Biocon Share Price
(BIOCON)
Check the latest share price of Biocon, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
₹318.85
as on 04:01PM, 29 Apr 2025
NSE
Biocon Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹316.7Day's Price Range₹323.8552 Week's Low
52 Week's High
₹269.5552-Week Price Range₹404.7
| Returns % | |
| 1 Month Return | -5.01 % |
| 3 Month Return | -17.14 % |
| 1 Year Return | + 19.34 % |
| Market Stats | |
| Previous Close | ₹320.85 |
| Open | ₹321.00 |
| Volume | 12.14L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹38,004.99Cr |
Biocon Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹38,004.99 Cr
Return on Equity (ROE)
1.08
Return on capital employed (ROCE)
1.72
P/B Ratio
4.96
Dividend Yield
0.15
EPS (TTM)
6.43
Sector
Pharmaceuticals
How to invest in Biocon
Investing in Biocon is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Biocon or BIOCON on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Biocon or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Biocon with just a few clicks!
Biocon Valuation
Track how the P/E of Biocon has moved over time to understand valuation trends.
Biocon in the last 5 years
Lowest (30.85x)
October 1, 2019
Industry (58.33x)
December 15, 2023
Today (60.36x)
December 15, 2023
Highest (118.86x)
September 27, 2018
Today’s Price to Earnings Ratio: 60.36x
Analysts Recommendation on Biocon
Get updated buy, sell, and hold recommendations by analysts on Biocon.
based on 21 analysts
52.38%
Buy
28.57%
Hold
19.05%
Sell
52.38% of analysts recommend a 'BUY' rating for Biocon. Average target of ₹290.43
Source: S&P Global Market Intelligence
Analysts Forecast on Biocon
Get share price movements and forecasts by analysts on Biocon.
Biocon price forecast by 21 analysts
Downside of
High
₹400
Target
₹290.43
Low
₹230
Biocon target price ₹290.43, a slight downside of -8.25% compared to current price of ₹318.85. According to 21 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon revenue growth forecast
Expected growth rate Q1, FY2025:66.88%
Forecast
Actual
Including amortisation and stock based compensations
Biocon EPS growth forecast
EPS estimate Q1, FY2025:222.86%
Forecast
Actual
Source: S&P Global Market Intelligence
Biocon Financials
Get the annual and quarterly financial summary of Biocon, including revenue, profit, loss and more.
Biocon Index Inclusions
Biocon Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Biocon.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 10.2% | 0.00 | |
| Mutual Funds | 7.19% | 0.00 | |
| Retail Investors | 16.71% | 0.00 | |
| Others | 5.25% | 0.00 |
Biocon vs Peers
Compare market cap, revenue, PE, and other key metrics of Biocon with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹38,004.99 Cr | -1.21% | 0.51 | NA | NA | |
| HOLD | ₹1,48,378.35 Cr | 26.67% | 0.50 | NA | NA | |
| BUY | ₹1,05,894.82 Cr | 34.5% | 0.68 | NA | NA | |
| HOLD | ₹22,962.93 Cr | -4.68% | 0.50 | NA | NA | |
| BUY | ₹1,18,158.42 Cr | 29.4% | 0.50 | NA | NA |
Biocon News & Key Events
Latest news and events at one place to help you take investing decisions in Biocon.
Biocon Shares Surge on Positive EU Biosimilar Review - 28 Apr, 2025
Biocon Ltd's shares increased by 3.3% following positive recommendations from the European Medicines Agency for its denosumab biosimilars. This development enhances Biocon's global market presence and boosts investor confidence.Biocon Plans Major Fundraising for Growth - 24 Apr, 2025
Biocon's board has approved raising up to ₹4,500 crore through various methods to support future growth plans. The company also reported a significant decline in net profit for Q3 FY25.Biocon Plans Major Fundraising Initiative - 23 Apr, 2025
Biocon Limited's board has approved a plan to raise up to ₹4,500 crore through various securities, including equity and debt instruments, to strengthen its financial position and support growth initiatives.Biocon Board Meeting to Discuss Fundraising Proposal - 20 Apr, 2025
Biocon Limited's board meeting on April 23, 2025, will consider a fundraising proposal to strengthen its balance sheet and support growth initiatives. The company may raise funds through various methods, pending approvals.Biocon Secures U.S. Launch for Yesafili Biosimilar - 15 Apr, 2025
Biocon Biologics has reached a settlement with Regeneron to commercialize Yesafili, an interchangeable biosimilar to Eylea, in the U.S. by 2026. This agreement enhances Biocon's presence in ophthalmology and includes a similar launch in Canada by July 2025.Biocon Biologics Secures FDA Approval for Jobevne - 10 Apr, 2025
Biocon Biologics has received U.S. FDA approval for Jobevne, a biosimilar to Bevacizumab, enhancing its oncology portfolio. This marks the seventh biosimilar approved in the U.S., reflecting Biocon's commitment to affordable biologics.Biocon Pharma Issues Recall for Cholesterol Medication - 09 Apr, 2025
Biocon Pharma Inc is recalling 2,184 bottles of a cholesterol medication due to failed dissolution specifications, as stated by the USFDA. The Class II recall was initiated on March 17, 2025.Biocon Faces Stock Drop Amid Fundraising and Tariff Concerns - 07 Apr, 2025
Biocon's board approved raising up to ₹600 crore through commercial papers, leading to a 6% drop in shares. Broader market concerns over US tariffs further impacted stock performance.Biocon Board Approves Rs. 600 Crore Paper Issuance - 04 Apr, 2025
Biocon Limited's Board of Directors has approved raising up to Rs. 600 crore through the issuance of commercial papers via private placement, aimed at enhancing liquidity and operational flexibility.Leadership Change and Fundraising Plans at Biocon - 02 Apr, 2025
Peter Bains has stepped down as CEO of Biocon, moving to Syngene International. The board will meet on April 4 to discuss fundraising options following a significant profit decline.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 3.64K Cr → 3.87K Cr (in ₹), with an average increase of 5.8% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -16.0 Cr → 25.1 Cr (in ₹), with an average increase of 163.8% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 8.58% to 8.77% in Mar 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Vimta Labs Ltd has given 88.8% return, outperforming this stock by 84.0%
- NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 5.66% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Vimta Labs Ltd has given 195.0% return, outperforming this stock by 207.9%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 18.12% to 17.76% in Mar 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, BIOCON stock has moved down by -5.4%
About Biocon
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Revenue: ₹3,432.90Cr as on June 2024 (Q2 24)
Net Profit: ₹861.80Cr as on June 2024 (Q2 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Biocon
Check out the Mutual Funds with significant holdings in Biocon.
Futures and Options
View the latest movement in Biocon Futures & Options, including strike prices, expiry dates, and percentage changes.
FAQs
What is Biocon Ltd price today?
Biocon Ltd share price today stands at ₹318.85, Open: ₹321, Previous Close: ₹320.85, High: ₹323.85, Low: ₹316.7, 52 Week High: ₹404.7, 52 Week Low: ₹269.55.
How to Buy Biocon Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Biocon Ltd shares
What are today's traded volumes of Biocon Ltd?
Today's traded volume of Biocon Ltd(BIOCON) is 12.14L.
What is today's market capitalisation of Biocon Ltd?
Today's market capitalisation of Biocon Ltd(BIOCON) is ₹38,004.99 Cr.
What is the 52 Week High and Low Range of Biocon Ltd?
How much percentage Biocon Ltd is down from its 52 Week High?
Biocon Ltd (BIOCON) share price is ₹318.85. It is down -21.21% from its 52 Week High price of ₹404.7
How much percentage Biocon Ltd is up from its 52 Week low?
Biocon Ltd (BIOCON) share price is ₹318.85. It is up 18.29% from its 52 Week Low price of ₹269.55